Pliant Therapeutics, Inc. announced the discontinuation of the BEACON-IPF Phase 2b trial assessing bexotegrast for patients with idiopathic pulmonary fibrosis due to safety concerns raised by an ...

March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq ... Pliant has discontinued the BEACON-IPF Phase 2b trial evaluating bexotegrast in patients with idiopathic pulmonary fibrosis ...

BEACON-IPF discontinued following recommendation ... as Senior Vice President of CMC and Technical Operations at Chinook Therapeutics. Research and development expenses were $38.8 million, as ...